Developer docs
API playgroundTry for free, no card

Search company profiles

Segal Trials

Full company profile

uuid0008t2o

Namestring
Segal Trials
Legal namestring
Segal Trials
Websiteurl
segaltrials.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Segal Trials is a privately held, founder-led clinical research site network founded in 1998 by Scott D. Segal, MD, and Bonnie Segal, headquartered in Miami Lakes, Florida. The company operates six research sites across South Florida covering Phase I through Phase IV trials in psychiatry, neurology, addiction medicine, women's health, infectious disease, general medicine, and psychedelic research. Core technical infrastructure centers on a 9,000-square-foot Early Phase unit with 29 research beds at Miami Lakes Medical Research, an inpatient Larkin Behavioral Health Services site, dedicated Women's Health, Infectious Disease, and Psychedelic & Cannabis Research centers, plus assisted-living-facility and mobile-clinic access. The business runs on contract research revenue from pharmaceutical sponsors (AbbVie, Roche, Pfizer, J&J, Janssen, Teva, Boehringer Ingelheim, Usona) and CROs (IQVIA, Syneos), with pricing negotiated per study contract. Patient recruitment is a central competency, supported by a HIPAA-compliant database of over 100,000 volunteers, dedicated retention specialists, physician referral networks, and a refer-a-friend program offering $25–$75 per qualified referral. The company is certified to GCP, ICH, FDA 21 CFR Part 11, HIPAA, and SoCRA standards, and reports contributions to 65+ FDA-approved medications and 1,500+ studies across 75+ therapeutic indications. Strategic emphasis is on CNS, psychedelic, and women's health indications, with a January 2025 strategic partnership with Cybin Inc. anchoring participation in a multinational Phase 3 program for CYB003 in Major Depressive Disorder.

Short descriptiontext

Segal Trials is a privately held South Florida clinical research site network conducting Phase I–IV trials in psychiatry, neurology, addiction, women's health, infectious disease, and psychedelics for pharmaceutical sponsors and CROs across six research facilities.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMiami Lakes, United States
HQ citystring
Miami Lakes
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical research services, clinical trial site network, Phase I-IV trials, central nervous system research, patient recruitment services
Industry2 codes
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Medical and Diagnostic Laboratories6215
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Contract Clinical Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Clinical Trial Services
TypeProfessional Services
Description

Contract research services for pharmaceutical companies and CROs conducting Phase I-IV clinical trials. Revenue generated through study contracts for patient enrollment, data collection, and regulatory compliance services across psychiatry, neurology, addiction, general medicine, infectious diseases, psychedelics, and women's health therapeutic areas.

segaltrials.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details4 tiers
1One-day outpatient studies compensation
ModelUnit PricingBilling cadenceOne time
Notes

$250 compensation for Early Pregnancy Detection study; STI Studies offer compensation for single-day participation

segaltrials.com
2Outpatient study compensation
ModelUnit PricingBilling cadenceOne time
Notes

Up to $2,275 for Major Depressive Disorder outpatient; up to $2,250 for Fibromyalgia; up to $1,300 for Binge Eating Disorder

segaltrials.com
3Inpatient study compensation
ModelUnit PricingBilling cadenceOne time
Notes

Up to $8,700 for Stable Schizophrenia inpatient; up to $5,900 for Bipolar I Acute Mania inpatient

segaltrials.com
4Refer-a-friend program
ModelTransaction based/ take rateBilling cadenceOne time
Notes

$25 when referral signs informed consent and completes first visit; $50 when referral qualifies and is accepted into study

segaltrials.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Segal Trials operates a private network of clinical research sites across South Florida conducting Phase I-IV clinical trials for pharmaceutical sponsors and CROs. The company specializes in psychiatry, neurology, addiction, general medicine, infectious diseases, psychedelics research, and women's health, providing patient recruitment, data collection, quality assurance, and regulatory compliance services under contract with drug developers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 65+ FDA-approved medications and devices contributed to through clinical trial participation
+4 more records
Product overview1 text field

Segal Trials is a privately held network of clinical research sites conducting Phase I-IV trials across South Florida. The company operates a platform of six research facilities offering specialized services in psychiatry/neurology, addiction, general medicine, infectious diseases, psychedelics research, and women's health. Core offerings include Miami Lakes Medical Research (inpatient and early phase studies with 29 beds), the Center for Psychedelic & Cannabis Research (first private psychedelic research facility in Florida), Women's Health & General Medicine Site, Infectious Disease Site, Larkin Behavioral Health Services, and Assisted Living Facilities research. The company provides integrated services including patient recruitment (100,000+ volunteer database), quality assurance, and regulatory compliance, having contributed to 65+ FDA-approved medications.

Product and service5 records
1Clinical Research Trials (Phase I-IV)
CategoryClinical Trial Services
2Early Phase Studies
CategoryClinical Trial Services
3Psychiatric Health Research
CategoryClinical Trial Services
4Addiction Research
CategoryClinical Trial Services
5General Medicine Research
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-15
Description

Strategic partnership agreement for Cybin's multinational pivotal Phase 3 program evaluating CYB003 for adjunctive treatment of Major Depressive Disorder. The program aims to enroll approximately 550 patients across 40+ clinical sites in the US and Europe. Segal Trials serves as the first program member and strategic partner in this pivotal psychedelic research initiative.

2Compass Health Systems
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Private practice affiliation with Compass Health Systems, the largest behavioral healthcare practice in South Florida, providing access to specialized patient populations and helping meet enrollment goals.

segaltrials.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership for inpatient and early phase clinical research services at 1201 North 37th Ave, Hollywood, FL, expanding Segal Trials' capacity for complex psychiatric studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership for conducting clinical trials. AbbVie is one of many major pharmaceutical companies Segal Trials partners with for drug development research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership for conducting clinical trials as part of Segal Trials' work with international medical leaders.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership for conducting clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership for conducting clinical trials as one of the international medical leaders Segal Trials collaborates with.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership for conducting clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership for conducting clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CRO partnership for clinical trial management and coordination services.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CRO partnership for clinical trial management and coordination services.

12Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership for conducting clinical trials.

segaltrials.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Pharmaceutical sponsor partnership specifically for psychedelic research studies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical research site network running Phase I-IV trials across diverse indications, comparable in size and multi-therapeutic breadth to Segal Trials.

TypeBroad incumbent
Description

Global CRO (including legacy PRA Health Sciences) offering comprehensive clinical development services; competes for the same pharmaceutical sponsors and occasionally provides site network solutions.

TypeBroad incumbent
Description

Mid-to-large CRO offering full-service clinical development including site services; overlaps with Segal as both a potential CRO partner and indirect competitor for sponsor contracts.

TypeDirect peer
Description

Large multi-therapeutic clinical research site network operating across the US; directly comparable business model (multi-site SMO) competing for the same pharmaceutical and CRO sponsors as Segal Trials.

TypeDirect peer
Description

Network of clinical research sites with strong early-phase and CNS expertise; competes with Segal for Phase I-IV psychiatric, neurology, and addiction trials from the same sponsor base.

TypeBroad incumbent
Description

Largest global CRO and life sciences services firm; listed as a Segal partner but also a broad incumbent whose site services and technology offerings overlap with Segal's value proposition.

TypeDirect peer
Description

Clinical research site services organization with multi-therapeutic trial execution and patient recruitment capabilities similar to Segal's model.

TypeDirect peer
Description

Clinical research site network leveraging technology-enabled patient access; operates a comparable SMO model competing for sponsors seeking rapid enrollment.

TypeDirect peer
Description

Multi-site clinical research organization offering Phase I-IV trials across multiple therapeutic areas; directly comparable SMO model with similar sponsor relationships.

10WCCT Global
TypeDirect peer
Description

Early-phase clinical research site organization with strong Phase I and CNS capabilities; directly comparable in inpatient/early-phase capacity and therapeutic focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Segal Trials

Contract Clinical Research Servicessegaltrials.com

Segal Trials is a privately held South Florida clinical research site network conducting Phase I–IV trials in psychiatry, neurology, addiction, women's health, infectious disease, and psychedelics for pharmaceutical sponsors and CROs across six research facilities.

What Segal Trials does

Segal Trials is a privately held, founder-led clinical research site network founded in 1998 by Scott D. Segal, MD, and Bonnie Segal, headquartered in Miami Lakes, Florida. The company operates six research sites across South Florida covering Phase I through Phase IV trials in psychiatry, neurology, addiction medicine, women's health, infectious disease, general medicine, and psychedelic research. Core technical infrastructure centers on a 9,000-square-foot Early Phase unit with 29 research beds at Miami Lakes Medical Research, an inpatient Larkin Behavioral Health Services site, dedicated Women's Health, Infectious Disease, and Psychedelic & Cannabis Research centers, plus assisted-living-facility and mobile-clinic access. The business runs on contract research revenue from pharmaceutical sponsors (AbbVie, Roche, Pfizer, J&J, Janssen, Teva, Boehringer Ingelheim, Usona) and CROs (IQVIA, Syneos), with pricing negotiated per study contract. Patient recruitment is a central competency, supported by a HIPAA-compliant database of over 100,000 volunteers, dedicated retention specialists, physician referral networks, and a refer-a-friend program offering $25–$75 per qualified referral. The company is certified to GCP, ICH, FDA 21 CFR Part 11, HIPAA, and SoCRA standards, and reports contributions to 65+ FDA-approved medications and 1,500+ studies across 75+ therapeutic indications. Strategic emphasis is on CNS, psychedelic, and women's health indications, with a January 2025 strategic partnership with Cybin Inc. anchoring participation in a multinational Phase 3 program for CYB003 in Major Depressive Disorder.

Segal Trials firmographics

Firmographics
Name
Segal Trials
Legal name
Segal Trials
Website
https://segaltrials.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Short description
Segal Trials is a privately held South Florida clinical research site network conducting Phase I–IV trials in psychiatry, neurology, addiction, women's health, infectious disease, and psychedelics for pharmaceutical sponsors and CROs across six research facilities.
Ownership category
akta.pro rank

Segal Trials industry classification

Industry
Product category
Contract Clinical Research Services
NAICS
Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGACAE
Clinical Trial Site Operations & Study Coordination
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Clinical research services
  • Clinical trial site network
  • Phase I-IV trials
  • Central nervous system research
  • Patient recruitment services

Where Segal Trials is headquartered

Location

Headquarters

HQ city
Miami Lakes
HQ country
United States
HQ region
North America

Offices7 records

Markets served

Segal Trials business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Clinical Trial Services: Contract research services for pharmaceutical companies and CROs conducting Phase I-IV clinical trials. Revenue generated through study contracts for patient enrollment, data collection, and regulatory compliance services across psychiatry, neurology, addiction, general medicine, infectious diseases, psychedelics, and women's health therapeutic areas.

Pricing tiers

ModelBillingPrice
Unit PricingOne timeOne-day outpatient studies compensation
Unit PricingOne timeOutpatient study compensation
Unit PricingOne timeInpatient study compensation
Transaction based/ take rateOne timeRefer-a-friend program

Go-to-market motion2 records

Distribution channels4 records

Marketing channels10 records

Segal Trials product offering

Product offering

Core offering

Segal Trials operates a private network of clinical research sites across South Florida conducting Phase I-IV clinical trials for pharmaceutical sponsors and CROs. The company specializes in psychiatry, neurology, addiction, general medicine, infectious diseases, psychedelics research, and women's health, providing patient recruitment, data collection, quality assurance, and regulatory compliance services under contract with drug developers.

Product overview

Segal Trials is a privately held network of clinical research sites conducting Phase I-IV trials across South Florida. The company operates a platform of six research facilities offering specialized services in psychiatry/neurology, addiction, general medicine, infectious diseases, psychedelics research, and women's health. Core offerings include Miami Lakes Medical Research (inpatient and early phase studies with 29 beds), the Center for Psychedelic & Cannabis Research (first private psychedelic research facility in Florida), Women's Health & General Medicine Site, Infectious Disease Site, Larkin Behavioral Health Services, and Assisted Living Facilities research. The company provides integrated services including patient recruitment (100,000+ volunteer database), quality assurance, and regulatory compliance, having contributed to 65+ FDA-approved medications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Clinical Research Trials (Phase I-IV)
  • Early Phase Studies
  • Psychiatric Health Research
  • Addiction Research
  • General Medicine Research

Quantifiable outcome

  • 65+ FDA-approved medications and devices contributed to through clinical trial participation
  • +4 more outcomes

Companies that use Segal Trials

Customer profile

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Segal Trials technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Segal Trials partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core.

  • Cybin Inc.coreStrategic or Co-development Partner · 15 January 2025Strategic partnership agreement for Cybin's multinational pivotal Phase 3 program evaluating CYB003 for adjunctive treatment of Major Depressive Disorder. The program aims to enroll approximately 550 patients across 40+ clinical sites in the US and Europe. Segal Trials serves as the first program member and strategic partner in this pivotal psychedelic research initiative.
  • Compass Health SystemscoreStrategic or Co-development PartnerPrivate practice affiliation with Compass Health Systems, the largest behavioral healthcare practice in South Florida, providing access to specialized patient populations and helping meet enrollment goals.
  • Larkin Behavioral Health ServicescoreStrategic or Co-development PartnerPartnership for inpatient and early phase clinical research services at 1201 North 37th Ave, Hollywood, FL, expanding Segal Trials' capacity for complex psychiatric studies.
  • AbbViecoreStrategic or Co-development PartnerPharmaceutical sponsor partnership for conducting clinical trials. AbbVie is one of many major pharmaceutical companies Segal Trials partners with for drug development research.
  • RochecoreStrategic or Co-development PartnerPharmaceutical sponsor partnership for conducting clinical trials as part of Segal Trials' work with international medical leaders.
  • TevacoreStrategic or Co-development PartnerPharmaceutical sponsor partnership for conducting clinical trials.
  • Johnson & JohnsoncoreStrategic or Co-development PartnerPharmaceutical sponsor partnership for conducting clinical trials as one of the international medical leaders Segal Trials collaborates with.
  • PfizercoreStrategic or Co-development PartnerPharmaceutical sponsor partnership for conducting clinical trials.
  • JanssencoreStrategic or Co-development PartnerPharmaceutical sponsor partnership for conducting clinical trials.
  • IQVIAcoreStrategic or Co-development PartnerCRO partnership for clinical trial management and coordination services.
  • SyneoscoreStrategic or Co-development PartnerCRO partnership for clinical trial management and coordination services.
  • Boehringer IngelheimcoreStrategic or Co-development PartnerPharmaceutical sponsor partnership for conducting clinical trials.
  • UsonacoreStrategic or Co-development PartnerPharmaceutical sponsor partnership specifically for psychedelic research studies.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Segal Trials competitors and assessment

Company assessment

Direct peers

  • Flourish Research: Clinical research site network running Phase I-IV trials across diverse indications, comparable in size and multi-therapeutic breadth to Segal Trials.
  • Velocity Clinical Research: Large multi-therapeutic clinical research site network operating across the US; directly comparable business model (multi-site SMO) competing for the same pharmaceutical and CRO sponsors as Segal Trials.
  • CenExel: Network of clinical research sites with strong early-phase and CNS expertise; competes with Segal for Phase I-IV psychiatric, neurology, and addiction trials from the same sponsor base.
  • ClinEdge: Clinical research site services organization with multi-therapeutic trial execution and patient recruitment capabilities similar to Segal's model.
  • Elligo Health Research: Clinical research site network leveraging technology-enabled patient access; operates a comparable SMO model competing for sponsors seeking rapid enrollment.
  • Wake Research: Multi-site clinical research organization offering Phase I-IV trials across multiple therapeutic areas; directly comparable SMO model with similar sponsor relationships.
  • WCCT Global: Early-phase clinical research site organization with strong Phase I and CNS capabilities; directly comparable in inpatient/early-phase capacity and therapeutic focus.

Broad incumbents

  • ICON plc: Global CRO (including legacy PRA Health Sciences) offering comprehensive clinical development services; competes for the same pharmaceutical sponsors and occasionally provides site network solutions.
  • Medpace: Mid-to-large CRO offering full-service clinical development including site services; overlaps with Segal as both a potential CRO partner and indirect competitor for sponsor contracts.
  • IQVIA: Largest global CRO and life sciences services firm; listed as a Segal partner but also a broad incumbent whose site services and technology offerings overlap with Segal's value proposition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Segal Trials social profiles

Digital presence

Segal Trials compliance and trust

Trust signal

Compliance4 records

Segal Trials financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Segal Trials leadership team

Management profile

Number of profiles

Profiles9 records

Segal Trials funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Segal Trials M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Segal Trials

What does Segal Trials do?

Segal Trials operates a private network of clinical research sites across South Florida conducting Phase I-IV clinical trials for pharmaceutical sponsors and CROs. The company specializes in psychiatry, neurology, addiction, general medicine, infectious diseases, psychedelics research, and women's health, providing patient recruitment, data collection, quality assurance, and regulatory compliance services under contract with drug developers.

Is Segal Trials a public or private company?

Segal Trials is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Segal Trials founded?

Segal Trials was founded in 1998. It employs 101 to 250 people.

Where is Segal Trials based?

Segal Trials is headquartered in Miami Lakes, United States, in the North America region.

How does Segal Trials make money?

One revenue line is on record: clinical Trial Services.

Who are Segal Trials's main competitors?

Direct peers on record are Flourish Research, Velocity Clinical Research, CenExel, ClinEdge, Elligo Health Research, Wake Research and WCCT Global. Broad incumbents are ICON plc, Medpace and IQVIA.

Does Segal Trials have an API?

No public API is recorded for Segal Trials.

What industry is Segal Trials in?

Segal Trials's product category is Contract Clinical Research Services. Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialPsychedelicnewsbreaks Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Launches Strategic Partnership Program With Segal Trials For Phase 3 MDD StudyCybin Inc. launched a strategic partnership program with Segal Trials for a Phase 3 study of its deuterated psilocybin analog CYB003 for major depressive disorder. The company also develops CYB004 for generalized anxiety disorder and operates in multiple countries.FinancialContent Business PageSegal Trials Kicks Off CISCRP’s 8th Annual Medical Heroes Appreci-A-ThonOver 90 Segal Trials employees joined CISCRP's 8th Annual Medical Heroes Appreci-A-Thon, a two-week event combining physical activity and fundraising. Just two days into the challenge, the company raised $2,500 and logged over 81,000 Footprint Points. The event runs September 1–15 to support CISCRP's patient education mission.BioSpaceSegal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR StudySegal Trials announced its participation in MapLight Therapeutics' Phase 2 ZEPHYR trial for acute schizophrenia, with its Miami Lakes site enrolling patients. The company has completed over 380 schizophrenia trials and enrolled more than 3,700 participants. Segal Trials remains committed to partnering with sponsors to advance schizophrenia therapies.FinancialContent Business PageSegal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR StudySegal Trials participated as one of 25 U.S. research sites in MapLight Therapeutics’ Phase 2 ZEPHYR clinical trial evaluating the investigational therapy ML-007C-MA for acute schizophrenia exacerbations. Segal Trials served as a high-enrolling site for the study, which recently reported topline results from its multicenter execution.Business Wire BlogSegal Trials Reinforces Leadership in Acute Schizophrenia Research Following Participation in MapLight Therapeutics’ Phase 2 ZEPHYR StudySegal Trials announced its participation as one of the highest-enrolling sites in the Phase 2 ZEPHYR clinical trial for MapLight Therapeutics' investigational schizophrenia therapy, ML-007C-MA. The study evaluated the drug's efficacy in treating acute exacerbations of schizophrenia in adults. This involvement reinforces Segal Trials' established leadership and extensive experience in acute schizophrenia research.Business Wire BlogAs Federal Fast-Tracking Accelerates Psychedelic Therapies, Segal Trials Is Positioned to Support the Next Phase of Clinical DevelopmentSegal Trials is positioned to support the next phase of psychedelic clinical development as the FDA accelerates review. The company has completed over 60 dosing sessions across seven DEA Schedule I compounds since 2018. Its purpose-built dosing rooms and trained team are critical for executing these studies safely.Stock TitanCybin Launches Phase 3 Trial for Depression Drug After Breakthrough 71% Remission RateCybin launched its Phase 3 trial for CYB003 in major depressive disorder, partnering with Segal Trials as the first program member. Phase 2 data showed 71% remission from depression symptoms for 12 months with two 16-mg doses. The company plans to enroll about 550 patients across 40+ sites in the US and Europe.Business Wire BlogCybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive DisorderCybin announced its first strategic partnership agreement with Segal Trials to support its Phase 3 program evaluating CYB003 for major depressive disorder. The company plans to enroll about 550 patients across over 40 sites in the U.S. and Europe. The partnership aims to improve site efficiency and accelerate the approval process.PR NewswireSegal Trials Acquires New Studies with Schedule 1 DEA License and Continues to Expand its Network of Inpatient and Outpatient FacilitiesSegal Trials, a privately held clinical research network based in South Florida and South Carolina, has been selected as one of seven sites to participate in Usona Institute's Phase II PSIL201 study investigating psilocybin for major depressive disorder. The company, which holds a Schedule 1 DEA License, recently opened a new 29-bed clinical research facility in Miami Lakes, Florida, expanding its network to seven sites focused on psychiatry, neurology, and women's health trials.